Leadership:
Co-Founder |
Adam Kaplin, MD, PhD
Dr. Adam Kaplin, a neuropsychiatrist trained at Yale and Johns Hopkins, combines extensive startup experience with deep expertise in CNS drug development. He is dedicated to advancing groundbreaking treatments for neurological and psychiatric disorders, bringing visionary leadership to Minerve Pharmaceuticals.
Co-Founder |
Jonathan Helfgott, MS
Jonathan Helfgott is a regulatory expert with extensive experience and strong ties to the FDA. He specializes in guiding CNS drug development with strategic regulatory insight and ensuring compliance, accelerating the pathway from innovation to patient care.
Chairman and Advisor|
David Vorhoff
David Vorhoff, Chairman of Foro, brings a wealth of expertise in finance and business development. His strategic vision and leadership support Minerve’s growth and long-term success.
Scientific Advisory Board |
Zaven Khachaturian, PhD
Dr. Zaven Khachaturian, a pioneer in Alzheimer’s research, provides invaluable guidance on scientific and therapeutic strategy. His groundbreaking work has shaped the understanding and treatment of neurodegenerative diseases.
Scientific advisory Board |
Ara Khachaturian, PhD
Dr. Ara Khachaturian, Ph.D. is a leader in public health policy, specializing in epidemiology, biomedical research, and complex modeling. He is Executive Vice-President of Prevent Alzheimer’s 2020, Inc. and founding Executive Editor of the Alzheimer’s & Dementia journal series. Dr. Khachaturian is also a Senior Research Fellow at the National Supercomputing Institute at UNLV.
Scientific advisory Board |
Michael Levy, MD, PhD
Dr. Michael Levy, Director of the Neuroimmunology Clinic at Harvard’s Massachusetts General Hospital, provides critical expertise in neuroimmunology, supporting Minerve’s mission to address neurodegenerative diseases with innovative therapeutic strategies.
Intellectual Property Development |
Richard Warburg
Richard Warburg and his team at Godney Holdings deliver comprehensive intellectual property strategy and management, ensuring Minerve Pharmaceuticals’ innovations are protected and positioned for success in a competitive market.
In House Legal Counsel |
Mark Bardondess, Esq.
Mark brings decades of exceptional legal expertise to his role as the in-house legal counsel of Minerve Pharmaceuticals.
A seasoned attorney with a distinguished career spanning corporate law, intellectual property, and pharmaceutical regulations, Mark specializes in providing strategic legal guidance tailored to the complexities of innovative drug development.
Executive Director of Scientific Affairs |
Anupama Kumar, MBBS.
Dr. Anupama Kumar, a research leader with post-doctoral training from Johns Hopkins in neuroimmunology and psychiatry , combines extensive drug development experience with deep expertise in clinical trials for neurological and psychiatric disorders. She is dedicated to translating scientific innovation into practical therapeutic applications, bringing results-driven leadership to her role.